Sponsoring Agency HHS
    POP 9/22/15 - 9/21/18 (2 years)


The Division of Cancer Prevention (DCP) of the National Cancer Institute (NCI) has awarded a Master IDIQ under the Preclinical PREVENT Cancer Program for Preclinical Efficacy and Intermediate Endpoint Biomarkers. The contractl supports the development of potential cancer preventive agents or vaccines employing detailed preclinical efficacy studies and determining pharmacodynamics efficacy, and biomarkers, which parallel the effectiveness of a given agent. The primary endpoint of the efficacy studies shall be to prevent the development of invasive cancers whereas the biomarker studies will identify endpoints which correlate with the effectiveness of a given preventive agent or vaccine. These endpoints might be measured in body fluids, normal or at risk tissue from the target or in histopathlogically altered tissue from the target organ(s).

  • $6.8m Aggregate Dollars Obligated
  • $6.8m Aggregate Base & Exercised Options
  • $6.8m Aggregate Base & All Options (Ceiling)

Market Stats Related Contracts